SCHEMBL7086734

SCHEMBL7086734

COc1ccc(NS(=O)(=O)c2ccc(Cl)c3ccccc23)cc1N1CCN(C)CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 19/20 0.67
HTR1A P08908 3/20 0.59
HTR1D P28221 3/20 0.59
HTR1B P28222 3/20 0.59
HTR2A P28223 3/20 0.59
HTR2C P28335 3/20 0.59
HTR7 P34969 3/20 0.59
DRD2 P14416 2/20 0.59
HTR1E P28566 2/20 0.59
HTR1F P30939 2/20 0.59
ADRA1B P35368 2/20 0.59
DRD3 P35462 2/20 0.59
HTR2B P41595 2/20 0.59
HTR4 Q13639 2/20 0.59
CYP1A2 P05177 1/20 0.59
CYP3A4 P08684 1/20 0.59
CYP2D6 P10635 1/20 0.59
CYP2C19 P33261 1/20 0.59
KDM4E B2RXH2 1/20 0.59
MEN1 O00255 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7081522 0.94 HTR6 (0.72) HTR6HTR1AHTR1DHTR1BHTR2A
SCHEMBL6974970 0.88 HTR6 (0.72) HTR6HTR1AHTR1DHTR1BHTR2A
SCHEMBL6976677 0.87 HTR6 (0.69) HTR6HTR1AHTR1DHTR1BHTR2A
SCHEMBL6980564 0.86 GHSR (0.71) HTR6HTR1AHTR1DHTR1BHTR2A
SCHEMBL6975520 0.84 HTR6 (0.68) HTR6HTR1AHTR1DHTR1BHTR2A
SCHEMBL6981515 0.83 HTR6 (0.76) HTR6HTR1AHTR1DHTR1BHTR2A
SCHEMBL6977605 0.83 HTR6 (0.67) HTR6HTR1AHTR1DHTR1BHTR2A
SCHEMBL6971445 0.82 HTR6 (0.81) HTR6HTR1AHTR1DHTR1BHTR2A
SCHEMBL6975550 0.82 HTR6 (0.74) HTR6HTR1AHTR1DHTR1BHTR2A
SCHEMBL6976941 0.82 HTR6 (0.71) HTR6HTR1AHTR1DHTR1BHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0946539-B1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 2003-08-13 EP claimed
US-6599904-B2 5-HT6 receptor antagonists are believed to be of potential use in the treatment of certain CNS disorders; cognitive memory enhancement SMITHKLINE BEECHAM P.L.C. (GB) 2003-07-29 US disclosed